PCA3 has been shown to be useful to predict the presence of malignancy in men undergoing repeat prostate biopsy.
A PCA3 test may be offered. This is a new urine test which provides a more effective means of detecting prostate cancer than the PSA test. PCA3 is a chemical made particularly by prostate cancer cells.
FDA Advisory Panel for PROGENSA PCA3 Delayed
DiagnoCure, Inc. (TSX: CUR), a life sciences company that develops and commercializes highâvalue cancer diagnostic… more...
 See also: Cancer, Aging, Urology, Prostatectomy, Prostate Cancer
  
|
RSS
